NeoImmuneTech, Inc. and GI Innovation, both bioventures trading on South Korea’s Kosdaq market, have unveiled preliminary clinical data for their respective novel cancer immunotherapies either in combination with pembrolizumab or as monotherapy, which showed early promise in solid tumors. Both sets of results were presented at the recent Society for Immunotherapy of Cancer (SITC) 2022 annual meeting in Boston.
NeoImmuneTech, a US-based affiliate of Korean firm Genexine Inc., said efineptakin alfa (NT-I7), the only clinical-stage, long-acting human interleukin-7 therapy, showed clinical efficacy with pembrolizumab (Merck & Co., Inc.'s Keytruda) in relapsed/refractory gastrointestinal tumors